VolitionRx Limited (NYSE American: VNRX) has announced the publication of a peer-reviewed study detailing its proprietary Capture-Seq liquid biopsy technology, which the company says is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This breakthrough addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the large background of healthy cell-free DNA, enabling highly enriched tumor DNA datasets for cancer detection and monitoring.
The technology uses a two-step process that combines physical sample enrichment with bioinformatic filtering to produce ctDNA sequencing datasets with greater than 99% purity. Early validation studies demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have also produced encouraging findings, according to the company.
Volition is currently conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications. The company is advancing larger validation studies, working with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities.
The publication of this research marks a significant step forward in the field of liquid biopsy, which has been limited by the difficulty of detecting and analyzing the small fraction of tumor-derived DNA in blood. By achieving over 99% purity, Capture-Seq could improve the accuracy and reliability of cancer detection tests, potentially leading to earlier diagnosis and better patient outcomes. The technology’s potential applications extend beyond cancer detection to monitoring for minimal residual disease, which could help clinicians assess treatment effectiveness and detect recurrence earlier.
Volition is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, it is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The full press release is available at https://ibn.fm/nuJEs. For more information about Volition, visit the company’s website at https://volition.com/.
